USE OF AN IBAT INHIBITOR FOR THE TREATMENT OR PROFILAXIS OF CONSTIPATION.

摘要

The use of a compound selected from the group consisting of 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- (N - {(R) -alpha- [N - ((R) -1-carboxy-2-methylthioethyl) carbamoyl] -4-hydroxybenzyl} -carbamoylmethoxy) -2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- (N - {(R) -alpha- [N - ((S) -1-carboxy-2- (R) - hydroxypropyl) carbamoyl] -4-hydroxybenzyl} -carbamoylmethoxy) -2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- (N - {(R) -alpha- [N - ((S) -1-carboxy-2-methylpropyl) carbamoyl] -4-hydroxybenzyl} -carbamoylmethoxy) -2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- (N - {(R) -alpha- [N - ((S) -1-carboxybutyl) carbamoyl] -4-hydroxy -benzyl} car-bamoylmethoxy) - 2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- (N - {(R) -alpha- [N - ((S) -1-carboxypropyl) carbamoyl] benzyl} carbamoyl- methoxy) - 2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- (N - {(R) -alpha- [N - ((S) -1-carboxyethyl) carbamoyl] benzyl} carbamoyl- methoxy) -2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- (N - {(R) -alpha- [N - ((S) -1-carboxy-2- (R) - hydroxypropyl) carbamoyl] benzyl carbamoylmethoxy) -2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- (N - {(R) -alpha- [N- (2-sulfoethyl) carbamoyl] -4-hydroxybenzyl} carbamoyl-methoxy ) - 2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- (N - {(R) -alpha- [N - ((S) -1-carboxyethyl) carbamoyl] -4-hydroxybenzyl } -carbamoylmethoxy) -2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- (N - {(R) -alpha- [N - ((R) -1-carboxy-2-methylthioethyl) carbamoyl] benzyl} -carbamoylmethoxy) -2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- (N - {(R) -alpha- [N - {(S) -1- [N - ((S) - 2-hydroxy-1-carboxyethyl) carbamoyl] -propyl} -carbamoyl] benzyl} carbamoylmethoxy) -2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- (N - {- {(R) -alpha- [N - ((S) -1-carboxy-2-methylpropyl) carbamoyl] benzyl} -carbamoylmethoxy) -2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- (N - {(R) -alpha- [N - ((S) -1-carboxypropyl) carbamoyl] -4-hydroxybenzyl } carbamoylmethoxy) -2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- [N - ((R) -alpha-carboxy-4-hydroxybenzyl) carbamoylmethoxy] -2,3,4,5-tetrahydro - 1,2,5-benzothiadiazepine; 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- (N {(R) -alpha- [N- (2- (S) -3- (R) -4- ( R) -5- (R) -2,3,4,5,6-pentahydroxyhexyl) -carbamoyl] benzyl} carbamoylmethoxy) -2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; and 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- (N - {(R) -alpha- [N- (2- (S) -3- (R) -4 - (R) -S- (R) -2,3,4,5,6-pentahydroxyhexyl) carbamoyl] -4-hydroxybenzyl} carbamoylmethoxy) -2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine ; or a pharmaceutically acceptable salt, solvate, solvate of such salt, or an in vivo hydrolysable ester or an in vivo hydrolyzable amide thereof, in the manufacture of a medicament for use in the treatment and / or prophylaxis of constipation, in an animal of hot blood, just like man.